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Background: Chronic kidney disease (CKD) accelerates vascular stiffening related to age. Arterial stiffness may be
evaluated measuring the carotid-femoral pulse wave velocity (PWV) or more simply, as recommended by KDOQI,
monitoring pulse pressure (PP). Both correlate to survival and incidence of cardiovascular disease. PWV can also be
estimated on the brachial artery using a Mobil-O-Graph; a non-operator dependent automatic device. The aim was
to analyse whether, in a dialysis population, PWV obtained by Mobil-O-Graph (MogPWV) is more sensitive for
vascular aging than PP.
Methods: A cohort of 143 patients from 4 dialysis units has been followed measuring MogPWV and PP every 3 to
6 months and compared to a control group with the same risk factors but an eGFR > 30 ml/min.
Results: MogPWV contrarily to PP did discriminate the dialysis population from the control group. The mean
difference translated in age between the two populations was 8.4 years. The increase in MogPWV, as a function of
age, was more rapid in the dialysis group. 13.3% of the dialysis patients but only 3.0% of the control group were
outliers for MogPWV. The mortality rate (16 out of 143) was similar in outliers and inliers (7.4 and 8.0%/year).
Stratifying patients according to MogPWV, a significant difference in survival was seen. A high parathormone (PTH)
and to be dialysed for a hypertensive nephropathy were associated to a higher baseline MogPWV.
Conclusions: Assessing PWV on the brachial artery using a Mobil-O-Graph is a valid and simple alternative, which,
in the dialysis population, is more sensitive for vascular aging than PP. As demonstrated in previous studies PWV
correlates to mortality. Among specific CKD risk factors only PTH is associated with a higher baseline PWV.
Trial registration: ClinicalTrials.gov Identifier: NCT02327962.
Keywords: Arterial stiffness, Hemodialysis, Mobil-o-graph, Pulse pressure, Pulse wave analysis, Pulse wave velocityBackground
Chronic hemodialysis patients should have arterial stiff-
ness evaluated monthly using Pulse Pressure as sug-
gested by KDOQI guidelines [1]. This recommendation
pursues a dual goal since it outlines the importance of
monitoring vascular stiffness in hemodialysis patients
[2-4] and, at the same time, emphasizes the fact that* Correspondence: luca.gabutti@eoc.ch
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unless otherwise stated.Pulse Pressure provides valuable information on tissue
perfusion characteristics [5]. Arterial stiffening in dialysis
patients is the result of aging and of non-specific and
End Stage Renal Disease (ESRD) related risk factors,
such as medial calcification, volume overload, uraemia-
related endothelial dysfunction, increased extracellular
matrix and intimal fibroelastic thickening [6]. Arterial
stiffness of the aorta and its major branches can be eval-
uated by measuring Pulse Wave Velocity (PWV) – e.g.
carotid-femoral Pulse Wave Velocity (“gold standard”)
[7] – or, alternatively, it can be estimated by Pulse Wavel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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artery [8-11]. In the first case, a doppler ultrasound de-
tector is used together with a software tool for data ana-
lysis. The second approach requires the use of a
sphygmomanometer, such as the Mobil-O-Graph, cap-
able of analysing the pulse wave morphology and of cal-
culating PWV [9-13]. The first methodology is complex,
operator-dependent and not routinely applicable,
whereas the second one is potentially exploitable in clin-
ical practice [9].
Coming back to arterial stiffness it is also important to
mention that the increase in PWV related to the above-
mentioned risk factors accelerates with age [7] and that
both, PWV and PP, correlate to mortality in the dialysis
population [14-16]. For each PWV increase of 1 m/s
Blacher et al. found an all-cause mortality-adjusted OR
of 1.39 (95% CI, 1.19 to 1.62) [15] while for each
10 mmHg increase in PP, Tozawa et al. found an in-
crease in all-cause mortality relative risk of 8% [16].
Risk factors such as age, hypertension, previous history
of heart diseases and diabetes influence the evolution of
Pulse Wave Velocity before dialysis initiation whereas
their impact during the course of dialysis has not yet
been demonstrated [17]. In this regard, a study pub-
lished in 2013 by Utescu et al. indicated that the only
risk factor significantly associated with PWV progression
was the level of an advanced glycation end-product
known as pentosidine [17]. The results of this study con-
firmed that specific uraemia-related risk factors can be
identified and possibly quantified.
In the above-mentioned study, the rate of PWV pro-
gression (+0.84 m/s per year) was surprisingly high, es-
pecially when projected over time as a function of the
average life span of ESRD patients on dialysis. Another
critical data point outlined in the study was the discrep-
ancy in the annual rate of change in carotid-femoral
compared to carotid-radial Pulse Wave Velocity, which
was +0.84 m/s per year and −0.66 m/s per year, respect-
ively. The authors of the study postulate that this dis-
crepancy may be due to anatomical differences between
central (elastic) and peripheral (muscular) arteries and
that the latter could deploy an adaptive response to cen-
tral aortic stiffening. Although interesting, these data
raise some concerns about the promising possibility of
using the brachial artery as a site for PWV estimation,
even if based on a non-operator dependent method.
Furthermore, another limitation identified in the lit-
erature currently available on prospective longitudinal
studies analysing the PWV behaviour on dialysis pa-
tients, is the lack of a control group made up of patients
with similar characteristics and co-morbidities but with-
out, or with a less severe, kidney disease [2,15,17].
In the light of this, we decided to test a Mobil-O-
Graph, a simple device estimating PWV (MogPWV)through a modified sphygmomanometer on the brachial
artery and to analyse the baseline and follow-up
MogPWV values in a cohort of dialysis patients and in a
control group with the same risk factors but an eGFR >
30 ml/min.
The aim of the study was answering the following 4
questions, which also reflect both the primary and the
secondary endpoints of the trial: 1. Is PWV estimated by
Mobil-O-Graph on the brachial artery more sensitive for
vascular aging and discriminates better the dialysis
population from the control group than pulse pressure?
(primary endpoint); 2. Is MogPWV progression during
dialysis faster compared to the rate calculated as a func-
tion of age on the basis of the data obtained at the inclu-
sion day? (secondary endpoint); 3. Are there specific risk
factors that correlate to baseline MogPWV? (secondary
endpoint); 4. Does mortality correlate to MogPWV?
(secondary endpoint).
Methods
According to the above cited aims, a multi-centre cohort
study was designed.
Hemodialysis patients were recruited from 4 dialysis
units located in the Italian-speaking part of Switzerland
(Ospedale la Carità, Locarno; Ospedale San Giovanni,
Bellinzona; Ospedale Civico, Lugano; Ospedale Beata
Vergine, Mendrisio), starting from January 2011. The
study was designed to last 30 months. Subjects of the
control group were recruited from patients hospitalized
at Ospedale la Carità, Locarno, for elective minor sur-
gery and waiting for transfer or discharge.
Inclusion criteria for the hemodialysis group: age 18
and older; ability to understand the information pre-
sented and to sign the informed consent; chronic
hemodialysis for at least 8 weeks. Exclusion criteria for
the hemodialysis group: mental illness; inability to
understand the information presented and to sign the
informed consent; acute disease requiring hospitalization
at the time of patient enrolment; evidence of stenosis of
the subclavian artery of the arm without shunt or of the
non-shunt arm chosen to be used for the Mobil-O-
Graph measurements; atrial fibrillation.
Inclusion criteria for the control group: age 18 and
older; ability to understand the information presented
and to sign the informed consent. Exclusion criteria for
the control group: mental illness; inability to understand
the information presented and to sign the informed con-
sent; evidence of stenosis of both subclavian arteries;
atrial fibrillation; eGFR(EPI) < 30 ml/min (CKD stage 4
and 5).
Non-invasive hemodynamic and MogPWV measure-
ments were performed the day of inclusion in the study
and repeated every 3 months the first year and then
every 6 months (the non-shunt arm or the right arm






Age yr 71.3 ± 11.9 72.0 ± 8.9 ns
Male sex no. (%) 77 (53.8) 71 (71.0) <0.01
Coexisting conditions no. (%)
Smoker 47 (32.9) 45 (45.0) ns
pack years 44.4 ± 19.6 57.6 ± 23.1 ns
Hypertension 130 (90.9) 86 (86.0) ns
Diabetes 54 (37.8) 32 (32.0) ns
HbA1c % 6.9 ± 1.6 6.6 ± 1.8 ns
Dyslipidaemia 86 (60.1) 52 (52.0) ns
Cholesterol total
mmol/L
4.5 ± 1.2 4.6 ± 1.5 ns
LDL cholesterol
mmol/L
2.7 ± 1.0 3.1 ± 1.3 ns
CVD 83 (58.0) 53 (53.0) ns
eGFR (EPI) ml/min/
1.73 m2
<15 67.2 ± 23.9 -
Proteinuria mg/mmol No data 23 ± 47 -
Anti-hypertensive therapy no. (%)
RAAS-inhibitors 64 (44.8) 64 (64.0) <0.01
Calcium-antagonists 48 (33.6) 30 (30.0) ns
Beta-blockers 61 (42.7) 35 (35.0) ns
Alpha-blockers 29 (20.3) 4 (4.0) <0.01
Diuretics 72 (50.3) 43 (43.0) ns
Follow-up months 16.4 ± 7.5 0 -
Duration of dialysis
months
40.3 ± 35.2 - -
Kt/V 1.47 ± 0.33 - -
Haemodynamics measures mean ± SD
Systolic Pressure
(peripheral) mmHg
126.2 ± 22.9 128.7 ± 17.5 ns
Diastolic Pressure
(peripheral) mmHg
74.8 ± 14.0 78.4 ± 12.5 <0.05
Systolic Pressure
(central) mmHg
114.8 ± 21.1 117.8 ± 16.6 ns
Diastolic Pressure
(central) mmHg
76.5 ± 14.1 79.9 ± 12.6 0.05
Peripheral resistances
s*mmHg/ml
1.4 ± 0.3 1.4 ± 0.2 ns
Cardiac output l/min 3.8 ± 0.6 3.9 ± 0.6 ns
Pulse Pressure mmHg 51.3 ± 15.1 50.3 ± 12.0 ns
Diabetics 53.5 ± 10.5 54.6 ± 12.9 ns
non-Diabetics 50.0 ± 17.2 48.3 ± 11.2 ns
CVD 50.8 ± 14.4 49.5 ± 12.1 ns
non-CVD 52.0 ± 16.2 51.1 ± 12.0 ns
Alx@75 % 25.1 ± 10.6 29.6 ± 10.0 <0.01
Refl. Coef. % 63.1 ± 7.5 64.8 ± 6.3 ns (0.06)
Table 1 Characteristics of the study population
(Continued)
MobPWV adjusted m/s 7.6 ± 2.1 6.4 ± 1.5 <0.01
Diabetics 7.9 ± 1.9 6.5 ± 1.5 <0.01
non-Diabetics 7.5 ± 2.2 6.4 ± 1.6 <0.01
CVD 7.8 ± 2.2 6.7 ± 1.4 <0.01
non- CVD 7.4 ± 2.0 6.1 ± 1.6 <0.01
MobPWV unadjusted m/s 10.6 ± 2.2 10.5 ± 1.7 ns
Diabetics 10.9 ± 2.0 10.7 ± 1.7 ns
non-Diabetics 10.5 ± 2.3 10.4 ± 1.7 ns
CVD 10.7 ± 2.3 10.8 ± 1.7 ns
non-CVD 10.5 ± 2.1 10.2 ± 1.6 ns
Labor results mean ± SD
Ionized calcium mmol/l 1.15 ± 0.09 No data
Diabetics 1.14 ± 0.08
non-Diabetics 1.16 ± 0.09
CVD 1.15 ± 0.09
non-CVD 1.15 ± 0.09
PTH pmol/l 28.9 ± 21.0 No data
Diabetics 26.1 ± 20.8
non-Diabetics 30.6 ± 21.0
CVD 28.8 ± 22.6
non-CVD 29.0 ± 18.7
Phosphate mmol/L 1.59 ± 0.44
Bicarbonate mmol/L 18.7 ± 8.1
MobPWV = PWV obtained by Mobil-O-Graph (adjusted by systolic blood
pressure and unadjusted); Alx@75 = augmentation index corrected at 75 beats
per minute; Refl. Coef. = reflection coefficient; CVD = cardiovascular disease
(coronary heart disease and/or cerebrovascular disease and/or peripheral arterial
disease); CHF = congestive heart failure; BMI = body-mass Index; RAAS = renin-angio-
tensin-aldosterone-system; DBW=dry body weight; ns = non-significant.
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gether with a comprehensive screening of general
(hypertension, diabetes, dyslipidaemia, smoking habit,
history of cardiovascular disease) and specific cardiovas-
cular risk factors for CKD patients (serum calcium,
phosphate and PTH). At the inclusion, anamnestic data
about the cause of kidney disease (biopsy proven or as-
sumed as by history and clinical data), data of dialysis
initiation, dialysis modality and prescriptions (including
ultrafiltration volume), dialysis quality (using the kt/V;
Daugirdas), medications including phosphate binders,
vitamin D and analogues, calcium agonists and antihy-
pertensive and routine laboratory tests (including
hemoglobin, bicarbonate and lipid profile) were also col-
lected. At the follow-up visits file information was
upgraded and changes protocolled.
The Mobil-O-Graph (I.E.M. GmbH, Stolberg, Germany),
an electronic blood pressure monitoring system equipped
with an arm cuff and a software tool for Pulse Wave
Figure 1 Pulse Pressure and age. Pulse Pressure progression as a function of age in both groups (P between groups n.s.).
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flection coefficient) was chosen for non-invasive
hemodynamic and PWV monitoring. The reliability of
the Mobil-O-Graph in estimating the PWV by PWA
(MogPWV) was demonstrated in previous studies
[10-12,18-22]. Hemodynamic parameters (peripheral
and central blood pressure, cardiac output, peripheral
vascular resistance) and MogPWV were recorded for
each subject 10 times randomly distributed during the
course of dialysis (or during the day before hospital
discharge for the patients of the control group) and
mean values were obtained. Eight Mobil-O-Graph
were employed for the study. Calibration was guaran-
teed by the supplying company.
Statistical analysis was performed using the R software
tool [23]. Starting from a multivariate model of MogPWVFigure 2 Pulse Wave Velocity and age. MogPWV progression as a
function of age in both groups. Native values above (P between
groups n.s.); after adjusting by systolic blood pressure below
(P between groups <0.001).as a function of all measured variables, using a "backward-
elimination", it was established that the essential variables
of the model were age and systolic blood pressure accord-
ing to the formula: E[MogPWV] = α + β1 * age + β2 * PAsyst.
The MogPWV values were then normalized by eliminating
the effect of systolic blood pressure, on the basis of the
above cited equation, independently obtained from the re-
sults of the two groups. Aware of the fact that systolic
blood pressure is a parameter already used in the algorithm
to calculate the MogPWV by PWA, normalisation was ap-
plied considering the strong intra-individual influence of
systolic blood pressure on MogPWV and the extreme vari-
ability of blood pressure during dialysis. MogPWV outliers
were defined as individuals with, Bonferroni corrected stu-
dentized residuals P values (of the measured PWV) of less
than 0.05.
To test the normality of the residuals the Shapiro’s test
and the QQ-plot were used while the homoscedasticity
was proven thanks to the Levene (for the homogeneity
of the variances) and the Breusch-Pagan (for the resid-
uals of the models) tests [24]. To verify the absence of ser-
ial correlation of the residuals and their independence, the
Durbin-Watson test was used [25]. Hemodynamic parame-
ters and laboratory results were compared using a t-test
and a Mann–Whitney U test. Contingency tables were ana-
lysed using the chi-square while the significance of the
odds-ratios was explored using the two-sided Fisher's Exact
Test [25].
In all cases, a P value ≤ 0.05 was considered statistically
significant.
The protocol of the study was approved by the local
ethics committee (Ethical Committee of the Canton
Ticino, CE 2550). Informed consent was obtained from
all patients prior to enrolment.
Results
Characteristics of the population
143 patients were included in the dialysis group and 100
in the control group (see Table 1 for details and
Figure 3 Pulse Wave Velocity and survival. Survival as a function of MogPWV. Kaplan-Meier curve depicting the probability of survival in two
subgroups of MogPWV (P 0.02; Relative risk 2.96).
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patients treated with RAAS-inhibitors and alpha-
blockers were the only significant difference between
groups. The presumed aetiology of ESRD in the dialysis
group, in descending order, was: hypertensive nephropathy
30%, diabetic nephropathy 25%, glomerulonephritis 15%,
polycystic kidney disease 12%, other identified causes 8%,
obstructive or post-pyelonephritic nephropathy 6%, intersti-
tial nephropathy 5%, unknown 3% (the aetiology of renal
disease was biopsy proven in 32% of the patients only).Intra-patient MogPWV value dispersion
Reproducibility of results was confirmed by the small
dispersion of the normalized intra-individual MogPWV
values (0.388 ± 0.264 and 0.450 ± 0.304 m/s for the dialy-
sis and control group respectively).Table 2 Analysis of the potential risk factors for a higher PWV
disease (coronary heart disease and/or cerebrovascular disea
Inliers
Dialysate calcium Low (1.25 mmol/L) 49
High (1.50 mmol/L) 74
Diabetes Yes 51
No 73








Serum Phosphate Low (<1.79 mmol/L) 91
High (>1.78 mmol/L) 33Relationship between MogPWV and Systolic Blood
Pressure
Systolic blood pressure significantly influenced MogPWV
in both groups: in the control group a systolic increase of
10 mmHg generates a MogPWV increase of 0.319 ±
0.014 m/s. The dialysis group featured a lower increase, i.e.
0.237 ± 0.025 m/s (P < 0.01).Discrimination sensitivity (primary endpoint)
Unlike Pulse Pressure (P between groups n.s. on a PP
against age distribution), MogPWV significantly dis-
criminates the dialysis population from the control
group (P <0.001) (Figures 1 and 2). 13.3 % (19 out of
143) of the dialysis patients were outliers for MogPWV
vs. 3.0% (3 out of 100) in the control group (P 0.001);
signifying that 13.3% of the dialysis patients, comparedvalue (for dichotomous variables); CVD = cardiovascular
se and/or peripheral arterial disease); ns = non-significant
Outliers P-value OR CI 95%
19 < 0.001
0
3 ns (0.06) 3.63 1.03-13.45
16
10 ns (0.08) 2.61 0.98-6.96
9
10 ns 1.29 0.49-3.39
9
17 ns 1.21 0.25-5.93
2
11 ns 1.11 0.42-2.96
8
18 <0.05 6.47 1.03-138.1
1
Figure 4 Pulse Wave Velocity and dialysis duration. Surface-plot
showing the relationship among months on dialysis, age
and MogPWV.
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pected elevated MogPWV value.MogPWV and aging
The mean horizontal difference between the two
MogPWV against age distributions (depicting the behav-
iour of the dialysis and control group) was 8.4 years
(95% CI: 3.8-12.9) meaning that the arteries of our dialy-
sis population were, on average, 8.4 years older than
controls. These findings suggest that the difference is ex-
clusively related to the extent of renal function impair-
ment, since other risk factors were comparable across
the two groups. The regression line for the dialysis
group, divided into 4 quartiles of age, was slightly but
significantly steeper than in the control group (0.230 ±
0.008 vs. 0.199 ± 0.008 m/s per year; P 0.05); while the
slope increases with age in both groups.
Mortality rate (secondary endpoint)
16 out of 143 dialysis patients died during the follow-up.
The aetiology was CVD in 9, oncological diseases in 3,
infection in 3 and severe post-operative bleeding in 1.
The mortality rate (11.2%) was similar in outliers and in-
liers (7.4 and 8.0 % per year). Patient stratification ac-
cording to the MogPWV showed a significant difference
in survival (Figure 3).
Risk factors for higher baseline MogPWV (secondary
endpoint)
Hypertensive nephropathy as a presumed cause for
ESRD (the systolic blood pressure corrected MogPWV
in hypertensive nephropathy, diabetic nephropathy,
glomerulonephritis, polycystic kidney disease, obstruct-
ive or post-pyelonephritic nephropathy and interstitialnephropathy was respectively: 8.606 ± 1.904, 7.587 ±
1.836, 7.285 ± 2.120, 6.616 ± 2.045, 7.228 ± 2.434 m/s),
higher PTH levels (inliers 27.4 ± 20.5; outliers 38.7 ± 21.8
pmol/L; P 0.03), lower serum calcium (inliers 1.16 ±
0.08; outliers 1.09 ± 0.11 mmol/L; P <0.001), lower
serum phosphate (inliers 1.60 ± 0.46; outliers 1.48 ±
0.27 mmol/L; n.s.; P < 0.05 in the dichotomous analysis;
Table 2 ) and lower dialysate calcium levels (P <0.001)
correlate with higher baseline MogPWV. See Table 2 for
details.
Progression of MogPWV in dialysis (secondary endpoint)
The progression of MogPWV in dialysis did not signifi-
cantly differ from the rate calculated, as a function of
age, thanks to the regression model using the data of
the inclusion day (0.165 ± 0.003 vs. 0.169 ± 0.002 m/s
per year) (see Figure 4 for the surface plot and Table 3
and Figure 5 for the details of MogPWV evolution as a
function of the follow-up visits). Comparing MogPWV
progression rate between survivors and deceased, a sig-
nificant difference was not demonstrated (see Figure 6).
MogPWV and ultrafiltration rate
The ultrafiltration rate did not correlate with MogPWV
(see Figure 7).
Discussion
The main goal of the study was to determine whether
Pulse Wave Velocity estimated by Pulse Wave Analysis
on the brachial artery through a Mobil-O-Graph, a
modified sphygmomanometer, is more sensitive for vas-
cular aging and arterial stiffness and therefore better
than Pulse Pressure, the KDOQI guidelines recom-
mended parameter for dialysis patient monitoring, in
discriminating a cohort of dialysis patients from a con-
trol group with the same co-morbidities but with a sig-
nificantly better renal function (stage 3 or less). The
results furthermore confirm that PWV estimated by
Mobil-O-Graph (MogPWV) is able to intercept a discrim-
inating vascular aging parameter between dialysis patients
and control group, which is otherwise undetectable via PP
measurement. The 8.4 years difference between the two
MogPWV distributions (95% CI 3.8-12.9 years) suggests
that the arteries of our dialysis patients were, on average,
8.4 years older compared to a control group with a similar
co-morbidity profile but a less compromised renal function.
Even if the difference in the antihypertensive medica-
tion profile between the two groups (more RAAS inhibi-
tors in the control group and more alpha-blockers in the
dialysis group), could have increased the magnitude of
the difference in vascular aging [26,27], the potential
source of bias should have been blunted by the adjust-
ment for systolic blood pressure applied to MogPWV.




Enrollment visit Follow-up visits
C 0 D 0 D 1 D 2 D 3 D 4 D 5 D 6 D 7
Number of subjects 100 143 130 120 112 99 66 17 6












70.1 ± 8.0 68.7 ±
12.5
Median 73.1 72.0 73.2 73.8 74.0 74.2 73.7 70.4 66.7
1st Qu. 66.2 65.4 66.3 67.5 68.2 68.6 68.0 64.7 59.6
3rd Qu. 77.6 80.1 80.5 80.9 81.1 81.4 81.1 74.4 76.4
MobPWV unadjusted m/s
(mean ± SD)
10.5 ± 1.7 10.6 ± 2.2 10.5 ± 2.0 10.5 ± 2.0 10.8 ± 1.9 10.8 ± 1.9 10.9 ± 2.0 10.0 ± 1.4 9.8±2.2
Median 10.65 10.80 10.60 10.50 10.80 11.00 11.00 10.10 9.40
1st Qu. 9.40 9.08 9.30 9.10 9.70 9.65 9.38 9.25 8.05
3rd Qu. 11.73 12.00 12.00 11.83 12.10 12.20 11.90 11.05 10.90
MobPWV adjusted m/s
(mean ± SD)
6.4± 6.9 ± 2.1 6.8± 6.9± 7.0± 7.1± 7.0± 6.3± 6.1±
Median 6.48 6.85 6.83 6.91 7.13 7.12 6.87 6.29 5.70
1st Qu. 5.37 5.53 5.52 5.70 5.79 6.07 5.81 5.39 4.28
3rd Qu. 7.37 8.39 8.07 8.31 8.37 8.42 8.14 7.07 7.71
Pulse Pressure mmHg
(mean ± SD)












50.5 ± 9.5 50.4 ± 7.0
Median 49.0 50.0 50.6 46.6 52.2 50.4 53.4 51.3 48.6
1st Qu. 42.8 41.0 40.5 39.3 44.3 41.8 46.2 43.1 44.7
3rd Qu. 55.5 59.9 61.3 56.2 60.7 59.7 64.6 56.8 56.5
Systolic BP peripheral mmHg
(mean ± SD)
















Median 127.5 124.0 124.5 118.0 124.0 127.0 129.5 126.0 123.5
1st Qu. 116.0 110.5 111.8 108.0 114.0 110.8 117.0 111.0 114.3
3rd Qu. 139.3 142.0 140.3 133.0 139.0 140.0 143.0 138.0 135.8
Diastolic BP peripheral mmHg
(mean ± SD)
















Median 80.0 72.0 74.5 70.0 73.0 73.0 76.0 74.0 71.5
1st Qu. 70.0 65.0 66.0 64.0 65.0 65.0 65.0 67.0 69.3
3rd Qu. 86.0 84.0 82.3 79.0 81.8 82.3 82.5 82.0 77.5
C 0 and D 0: inclusion visits for subjects of the control and dialysis groups respectively; D 1–7 follow-up visits for the dialysis group. The patients were included
progressively and for this reason, even if the drop out was only due to deaths, the number of patients decreases from visit 1 to visit 7.
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the exponential model and expressing the distribution of
the MogPWV as a function of age in the two groups, the
theoretical convergence point was found to be located
many decades before the start of dialysis. Taking into ac-
count the limits of such an analysis approach and the
potential sources of bias, the result suggests that the ac-
celeration of PWV worsening begins long before the on-
set of ESRD.
The results obtained, substantiate the efficacy of using
such a simple non-operator dependent device to measure
vascular stiffness in haemodialysis patients in clinical wards.However, the evidence gathered from this trial, as well
as previous ones, does not make it possible to ascertain
the extent to which MogPWV estimated on the brachial
artery, is representative of the actual carotid-femoral
PWV for this particular patient setting.
Even if a correlation between MogPWV and ultrafiltra-
tion rate during dialysis, in the present study, was not
demonstrated; we must also bear in mind that PWV is
subject to fluctuations during dialysis due to changes in
blood pressure, solute concentrations and circulating
volume [28-31]. Even before the start of the dialysis ses-
sion and during the interdialytic interval, the results
Figure 5 Pulse Wave Velocity at the inclusion and follow up visits. MogPWV are systolic blood pressure adjusted (above) and unadjusted (below)
values respectively. 0: inclusion visits for subjects of the control and dialysis groups respectively; 1–7: follow-up visits for the dialysis group. Values
are given in mean; SD is depicted.
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pressure and by volume overload. Furthermore, in the dia-
lysis setting it is obviously not possible to perfectly conform
to the recommendation 11 (recommendations 3 and 9 are
not pertinent to the use of a Mobil-O-Graph) of the current
guidelines to assess PWV, stating to avoid measurements in
unstable clinical situations [32].
Although our results were gathered during dialysis
with many potential sources of bias, they provideFigure 6 Comparison of MogPWV progression rate between survivors and
adjusted values. 1–5: follow-up visits. None of the deceased was evaluatedinteresting and intra-patients reproducible information
on vascular aging that could be of relevance for individ-
ual patients. Therefore, despite the above-mentioned
constraints, the results of this trial give the basis for the
concrete selection of patients potentially at high-risk (a
subgroup of outliers, accounting for 13.3% of our dialysis
population, who showed MogPWV levels above the 95%
CI), who could benefit from a customized management
in the attempt to slow down vascular aging and relateddeceased of the dialysis group. MogPWV are systolic blood pressure
at visit 6 and 7. Values are given in mean; SD is depicted.
Figure 7 Relationship between MogPWV and Ultrafiltration. A correlation was not demonstrated.
Salvadé et al. BMC Nephrology  (2015) 16:62 Page 9 of 10factors like vascular calcification; and this even if we
were unable to demonstrate, probably because of the
relatively small size of the population, a relationship be-
tween the outlier status and specific known risk factors
(except for elevated PTH levels).
In a previous longitudinal study in dialysis, Utescu
et al. were in turn unable to demonstrate the impact of
classical risk factors on PWV progression; this eventually
being also related to the limited caseload or to the fact
that the largest amount of pathological changes in the
vascular wall could have been accumulated years before
the beginning of dialysis.
Other risk factors identified during the trial, such as
serum ionized calcium under the lower limit of the nor-
mal distribution, serum phosphate ≤ 1.78 mmol/L, and
physiological vs. supra-physiological dialysate calcium,
were unexpected and may have been the result of the
treatment strategy deployed during dialysis (e.g. physio-
logical dialysate calcium is preferred in the absence of
intradialytic hypotension or other specific indications for
a positive calcium balance). Moreover, as suggested
above, the risk factors were detected during the trial
period and did not account for past or pre-dialysis patient
management strategies that might explain the MogPWV
outlier status. Emphasizing this hypothesis, evidence of
hypertensive nephropathy, although not biopsy proven in
most of the cases, as the aetiology of End Stage Renal Dis-
ease , correlated to higher MogPWV, as expected.
Since this trial shows no evidence of faster MogPWV
progression during dialysis vs. pre-dialysis cumulative
data (+0.165 vs. +0.169 m/s/year), we can assume, as
mentioned above, that the difference vs. controls pro-
gressively built up over the years preceding dialysis initi-
ation, most likely due to the severity of kidney
dysfunction being a specific risk factor, and, possibly, to
patient management strategies.
Moreover, the steeper curve depicting MogPWV as a
function of Blood Pressure in the control group confirms
that the vascular behaviour and the relationship PWV-Blood Pressure between groups is different. A lesser
PWV reversibility decreasing systolic blood pressure in
the dialysis group could be postulated.
Similarly to previous trials [15,33-35], mortality rates
were higher among patients with elevated MogPWV.
However age plays a fundamental role in MogPWV pro-
gression and, eventually due to the small number of pa-
tients who died during the trial period (16 out of 143;
11%), after adjusting for age, the difference in mortality
between MogPWV subgroups was no longer statistically
significant.
Conclusions
Estimating PWV on the brachial artery using a Mobil-
O-Graph is a valid and simple alternative to direct
measurement, is more sensitive for vascular aging and
discriminates better the dialysis population, identifying
at the same time the outliers, than Pulse Pressure. The
importance of early prevention of vascular stiffening is
once again outlined by the facts that the arteries of our
dialysis patients were, on average, 8.4 years older com-
pared to a similar population but with a significant bet-
ter renal function and that the acceleration of PWV
progression has been found to begin well before dialysis ini-
tiation. As demonstrated in previous studies, MogPWV
correlates to mortality. Among specific CKD risk factors,
only PTH correlates to higher baseline MogPWV. Add-
itional studies may contribute to further characterize risk
factors, susceptible to being influenced, associated with
MogPWV progression during dialysis.
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